VIP
VIP
Also known as: VIP Peptide, Vasoactive Intestinal Polypeptide, Aviptadil
Overview
Key Facts
Primary Goal: Research and therapeutic applications of VIP
Binds VPAC1 and VPAC2 receptors to activate cAMP-mediated anti-inflammatory cascades. Suppresses pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) in macrophages and dendritic cells.
Dosing Information
~1-2 minutes (plasma); tissue effects persist longer
50–200 mcg
1-4x daily (intranasal) or 1x daily (subcutaneous)
4-12 weeks, often longer under medical supervision
Benefits
- Potent anti-inflammatory and immune-regulatory effects
- Reduces neuroinflammation and supports blood-brain barrier integrity
- Restores regulatory T-cell (Treg) function for immune tolerance
- Protects intestinal and pulmonary mucosal barriers
- Used in CIRS (Chronic Inflammatory Response Syndrome) protocols
- Improves pulmonary function and reduces pulmonary hypertension
- Neuroprotective effects in neurodegenerative conditions
Side Effects
Mechanism of Action
Binds VPAC1 and VPAC2 receptors to activate cAMP-mediated anti-inflammatory cascades
Suppresses pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) in macrophages and dendritic cells
Promotes generation and function of CD4+CD25+ regulatory T-cells
Stabilizes mast cells and reduces histamine release
Protects endothelial barrier function and reduces vascular permeability
Inhibits NF-kB signaling pathway in inflammatory cells
Contraindications
Do not use this peptide if any of the following apply:
- Hypotension or blood pressure instability
- Active diarrheal illness
- Pregnancy or breastfeeding
- Concurrent use of strong vasodilators or antihypertensives (use with caution)
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Note: Protect from light. Do not freeze reconstituted solution.
Research Summary
VIP has been studied extensively since its discovery in 1970. Dr. Ritchie Shoemaker popularized its use in CIRS (mold illness) treatment protocols, where intranasal VIP demonstrated improvements in pulmonary artery pressure, quality of life, and inflammatory markers. The pharmaceutical form, aviptadil, entered Phase 2/3 trials for ARDS during COVID-19, showing improvements in respiratory function. Over 8,000 PubMed publications document VIP's anti-inflammatory, neuroprotective, and immunomodulatory properties. It is now one of the most commonly prescribed peptides in integrative and functional medicine.
Frequently Asked Questions
Common questions about VIP
UK-Specific Information
Exclusive data points and guidance for UK residents using VIP
UK Lab Testing
UK Lab Testing
Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.
Share on TikTok
Generate a trackable link to share this peptide information on TikTok